CAPILLARIES PROVIDE
Nutrients Supply
Oxygen Delivery
Waste Removal
Elderly patients have reduced capillary density
Older men and women have fewer capillaries in their muscles and they lose the ability to form them as efficiently as young people in response to training. Their capillaries also have less contacts with surrounding tissue. The levels of VEGF protein responsible for the formation of new blood vessels were reduced by 25-30%. In some studies by up to 50%.
What is VEGF
Gene Therapy?
Gene Therapy?
VEGF plasmids supplement the DNA of the cell the original DNA of the cell without changing or interacting with it. They cannot be passed to the next generations and persist in the nucleus temporarily.
05
VEGF Protein
secreted
06
New capillaries
form
03
Plasmid enters
the cell
02
Supercoiled VEGF
plasmids
01
Injection
04
Plasmid enters
the nucleus
Angiography before and after 6 months
from VEGF Plasmid administration
Before
After
Before
After
Before
After
RESULTS
Enhanced Tissue Oxygenation
The treatment group showed a 27% sustained increase in TcPO2 (Transcutaneous Oxygen Pressure ), peaking at 90.7 ± 4.9 mmHg by year two and maintaining 84.1 ± 1.8 mmHg at year five.
Increased Blood Flow
A 24% increase in Blood Flow Linear Velocity was observed at the 6-month mark, rising from 23.9 ± 2 cm/s to 29.7 ± 1.7 cm/s (+5.8 cm/s).
Improved Ankle-Brachial Index (ABI)
ABI in the treated group increased by 24% at 6 months.
Sustained Long-Term Effects
Positive outcomes were observed for 3–5 years post-treatment.
Enhanced Walking Distance
Walking distance improved by an average of 177% in PAD patients.
Notably, even patients with severe circulation issues (Stage III) experienced up to a remarkable 683% improvement
in walking distance.
in walking distance.
Enhanced Tissue Oxygenation
The treatment group showed a 27% sustained increase in TcPO2 (Transcutaneous Oxygen Pressure ), peaking at 90.7 ± 4.9 mmHg by year two and maintaining 84.1 ± 1.8 mmHg at year five.
Increased Blood Flow
A 24% increase in Blood Flow Linear Velocity was observed at the 6-month mark, rising from 23.9 ± 2 cm/s to 29.7 ± 1.7 cm/s (+5.8 cm/s).
Improved Ankle-Brachial Index (ABI)
ABI in the treated group increased by 24% at 6 months.
Sustained Long-Term Effects
Positive outcomes were observed for 3–5 years post-treatment.
Enhanced Walking Distance
Walking distance improved by an average of 177% in PAD patients.
Notably, even patients with severe circulation issues (Stage III) experienced up to a remarkable 683% improvement
in walking distance.
in walking distance.
PAD
Muscle performance and fatigue resistance can be restored by increasing microvasculature.
Low muscle oxygenation and low capillary-to-fiber ratio contribute to sarcopenia.
Muscle support in elderly: VEGF therapy can help reverse muscle aging by improving muscle size and blood flow, especially in type II fibers, as older adults naturally lose muscle capillaries and have a reduced ability to boost VEGF levels through exercise compared to younger people.
Sarcopenia prevention: VEGF plays a role in maintaining neuromuscular junctions (NMJs). Evidence suggests that age-related NMJ dysfunction is central to musculoskeletal decline.
VEGF MUSCLE EFFECTS
1
Increased capillary-to-fiber ratio
2
Enhanced oxygen transfer efficiency
3
Increased Endothelial Nitric Oxide
4
Improved VO₂max and muscle strength
5
Reduced muscle fatigue and soreness
6
Shortened post-exercise or injury recovery
Muscle performance and fatigue resistance can be restored by increasing microvasculature.
Low muscle oxygenation and low capillary-to-fiber ratio contribute to sarcopenia.
Muscle support in elderly: VEGF therapy can help reverse muscle aging by improving muscle size and blood flow, especially in type II fibers, as older adults naturally lose muscle capillaries and have a reduced ability to boost VEGF levels through exercise compared to younger people.
Sarcopenia prevention: VEGF plays a role in maintaining neuromuscular junctions (NMJs). Evidence suggests that age-related NMJ dysfunction is central to musculoskeletal decline.
VEGF MUSCLE EFFECTS
1
Increased capillary-to-fiber ratio
2
Enhanced oxygen transfer efficiency
3
Increased Endothelial Nitric Oxide
4
Improved VO₂max and muscle strength
5
Reduced muscle fatigue and soreness
6
Shortened post-exercise or injury recovery
MUSCLE
Accelerated hair regrowth and increased follicle size
in VEGF transgenic mice.
The hair follicles require a steady supply of oxygen and nutrients delivered by the blood vessels to maintain normal hair growth.
Hair loss in Peripheral Atherosclerotic Disease (PAD) occurs because narrowed arteries restrict blood flow
to the legs, leading to inadequate oxygen and nutrient delivery to the hair follicles.
to the legs, leading to inadequate oxygen and nutrient delivery to the hair follicles.
VEGF expression is significantly reduced in alopecic follicles compared to normal human hair follicles.
Anti-VEGF antibody lead to hair growth retardation
and reduced hair follicle size.
VEGF accelerates hair regrowth and increased follicle size.
VEGF HAIR EFFECTS
1
Improved scalp vascularization
3
Inhibited follicle miniaturization
2
Increased follicular nutrient delivery
4
Accelerated hair growth
Accelerated hair regrowth and increased follicle size
in VEGF transgenic mice.
The hair follicles require a steady supply of oxygen and nutrients delivered by the blood vessels to maintain normal hair growth.
Hair loss in Peripheral Atherosclerotic Disease (PAD) occurs because narrowed arteries restrict blood flow
to the legs, leading to inadequate oxygen and nutrient delivery to the hair follicles.
to the legs, leading to inadequate oxygen and nutrient delivery to the hair follicles.
VEGF expression is significantly reduced in alopecic follicles compared to normal human hair follicles.
Anti-VEGF antibody lead to hair growth retardation
and reduced hair follicle size.
VEGF accelerates hair regrowth and increased follicle size.
VEGF HAIR EFFECTS
1
Improved scalp vascularization
3
Inhibited follicle miniaturization
2
Increased follicular nutrient delivery
4
Accelerated hair growth
HAIR
Highest safety profile among
all gene therapies
all gene therapies
Plasmid VGF therapy (Neovasculgen, pl-VEGF165) has an exceptional safety record spanning over a decade of clinical use.
Over 10,000 patients with PAD have already received VEGF therapy, and more than 210 patients have been monitored in post-marketing surveillance studies, establishing one of the most comprehensive safety databases for gene therapy products.
Leave your contacts and we’ll get back
to you to schedule
a call
a call
The information provided on this website is for general informational purposes only and is not intended or implied
to be a substitute for professional medical advice, diagnosis,
or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment.
